Prior Authorization DRUG Guidelines

**Arranon (nelarabine)**

Date Developed: 9/3/13 by Albert Reeves MD  
Effective Date: 10/22/13  
Last Approval Date: 1/26/16, 1/24/17, 1/23/18, 1/22/19, 2/18/20, 8/3/21, 2/1/22, 1/31/23

**Pharmacologic Category:** Antineoplastic Agent, Antimetabolite;

**Authorization Criteria:** Treatment of relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma in patients ≥1 year of age following at least 2 chemotherapy regimens

**Dosage:**

**Adult**

I.V.: 1500 mg/m²/dose on days 1, 3, and 5; repeat every 21 days until transplant, disease progression, or unacceptable toxicity.

**Children and Adolescents:**

IV: 650 mg/m²/dose (various regimens depending on clinical situation; consult product information)

- **NOTE:** Adequate I.V. hydration recommended to prevent tumor lysis syndrome; allopurinol may be used if hyperuricemia is anticipated.

**Major adverse reactions and Black Box Warnings:**

>10%:

- Cardiovascular: Peripheral edema (15%), edema (11%)
  
  - Central nervous system: Fatigue (50%), fever (23%), somnolence (7% to 23%; grades 2-4: 1% to 6%), dizziness (21%; grade 2: 8% adults), headache (15% to 17%; grades 2-4: 4% to 8%), hypoesthesia (6% to 17%; grades 2/3: children 5%, adults 12%), pain (11%)

  - Dermatologic: Petechiae (12%)

  - Endocrine & metabolic: Hypokalemia (11%)

  - Gastrointestinal: Nausea (41%), diarrhea (22%), vomiting (10% to 22%), constipation (21%)
Hematologic: Anemia (95% to 99%; grade 4: 10% to 14%), neutropenia (81% to 94%; grade 4: children 62%, adults 49%), thrombocytopenia (86% to 88%; grade 4: 22% to 32%), leukopenia (38%; grade 4: 7%), neutropenic fever (12%; grade 4: 1%)

Hepatic: Transaminases increased (12%; grade 3: 4%)

Neuromuscular & skeletal: Peripheral neuropathy (12% to 21%; grades 2/3: 11% to 14%), weakness (6% to 17%; grade 4: 1%), paresthesia (4% to 15%; grades 2/3: 3% to 4%), myalgia (13%)

Respiratory: Cough (25%), dyspnea (7% to 20%)

1% to 10%:

Cardiovascular: Hypotension (8%), sinus tachycardia (8%), chest pain (5%)

Central nervous system: Ataxia (2% to 9%; grades 2/3: children 1%, adults 8%), confusion (8%), insomnia (7%), depressed level of consciousness (6%; grades 2-4: 2%), depression (6%), seizure (grade 3: 1% adults; grade 4: 6% children), motor dysfunction (4%; grades 2/3: 2%), amnesia (3%; grade 2: 1%), balance disorder (2%; grade 2: 1%), sensory loss (1% to 2%), aphasia (grade 3: 1%), attention disturbance (1%), cerebral hemorrhage (grade 4: 1%), coma (grade 4: 1%), encephalopathy (grade 4: 1%), hemiparesis (grade 3: 1%), hydrocephalus (1%), intracranial hemorrhage (grade 4: 1%), lethargy (1%), leukoencephalopathy (grade 4: 1%), loss of consciousness (grade 3: 1%), mental impairment (1%), nerve paralysis (1%), neuropathic pain (1%), nerve palsy (1%), paralysis (1%), sciatica (1%), sensory disturbance (1%), speech disorder (1%)

Endocrine & Metabolic: Hypocalcemia (8%), dehydration (7%), hyper-/hypoglycemia (6%), hyponagnesemia (6%)

Gastrointestinal: Abdominal pain (9%), anorexia (9%), stomatitis (8%), abdominal distension (6%), taste perversion (3%)

Hepatic: Albumin decreased (10%), bilirubin increased (10%; grade 3: 7%, grade 4: 2%), AST increased (6%)

Neuromuscular & skeletal: Arthralgia (9%), back pain (8%), muscle weakness (8%), rigors (8%), limb pain (7%), abnormal gait (6%), noncardiac chest pain (5%), tremor (4% to 5%; grade 2: 2% to 3%), dysarthria (1%), hyporeflexia (1%), hypertonia (1%), incoordination (1%)

Ocular: Blurred vision (4%), nystagmus (1%)
Renal: Creatinine increased (6%)

Respiratory: Pleural effusion (10%), epistaxis (8%), pneumonia (8%), sinusitis (7%), wheezing (5%), sinus headache (1%)

Miscellaneous: Infection (5% to 9%)

<1% (Limited to important or life-threatening): Craniospinal demyelination, neuropathy (peripheral) (similar to Guillain-Barré syndrome), opportunistic infection, pneumothorax, progressive multifocal leukoencephalopathy (PML), respiratory arrest, rhabdomyolysis, tumor lysis syndrome

Contraindications

There are no contraindications listed within the manufacturer’s labeling.

Adverse Effects:

Bone marrow suppression; CNS depression; Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirement; Tumor lysis syndrome

Neurotoxicity: [U.S. Boxed Warning]: Severe neurotoxicity, including mental status changes, severe somnolence, seizure, and peripheral neuropathy (ranging from numbness to motor weakness or paralysis), has been reported. Observe closely for signs and symptoms of neurotoxicity; discontinue if ≥ grade 2. Adverse effects associated with demyelination or similar to Guillain-Barré syndrome (ascending peripheral neuropathies) have also been reported. Neurologic toxicities may not fully return to baseline after treatment cessation. Neurologic toxicity is dose-limiting. Risk of neurotoxicity may increase in patients with concurrent or previous intrathecal chemotherapy or history of craniospinal irradiation.

References:


**Revision History:**
Date Approved by P&T Committee: 10/22/13
Date Reviewed/No Updates: 1/28/14 by C. Sanders MD
Date Approved by P&T Committee: 01/28/14
Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD
Date Approved by P&T Committee: 1/27/15
Date Reviewed/ Updated: 1/22/15 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/26/16
Date Reviewed/ No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/24/17
Date Reviewed/ No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/23/18
Date Reviewed/No Updates: 1/22/19 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/22/19
Date Reviewed/No Updates: 2/18/20 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 2/18/20
Date Reviewed/ Updated: 8/3/21 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 8/3/21
Date Reviewed/No Updates: 2/1/22 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 2/1/22
Date Reviewed/No Updates: 1/31/23 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/31/23
<table>
<thead>
<tr>
<th>Date</th>
<th>Update</th>
<th>Authors</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/24/17</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>1/23/18</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>1/22/19</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>2/18/20</td>
<td>No</td>
<td>Howard Taekman, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>8/3/21</td>
<td>Yes</td>
<td>Howard Taekman, MD; Robert Sterling, MD</td>
<td>Updated dosing and formatting changes</td>
</tr>
<tr>
<td>2/1/22</td>
<td>No</td>
<td>Howard Taekman, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>1/31/23</td>
<td>No</td>
<td>Howard Taekman, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
</tbody>
</table>